Inquiry Basket
Loading ......
Filter By Product Search for
A4GALT
A4GALT Full Name
alpha 1,4-galactosyltransferase
A4GALT Introduction
Alpha-1,4-galactosyltransferase (A4GALT) is a type II Golgi-localized glycosyltransferase encoded by the A4GALT gene, sometimes referred to by alternative names including Gb3 synthase, CD77 synthase, P1/Pk synthase and P1PK blood group enzyme. Its canonical biochemical activity is to catalyze the transfer of an α1,4-linked galactose from UDP-galactose to lactosylceramide to produce globotriaosylceramide (Gb3/CD77), a key globo-series glycosphingolipid that defines the P(k) antigen in the human P1PK blood group system and forms the cellular receptor for certain bacterial toxins such as Shiga and verotoxins. A4GALT is a foundational enzyme in glycosphingolipid biosynthesis, shaping the glycolipid composition of plasma membranes and thereby influencing membrane organization, cellular recognition and signal transduction pathways that are central to cell–cell interactions and host–pathogen biology.
Figure 1. The biochemical activity of α-1,4-galactosyltransferase (A4GALT) and its functional role in cells.
Functionally, A4GALT's biosynthetic product Gb3 serves not only as a blood group antigen but also as a determinant of cellular susceptibility to extracellular agents; Gb3 is recognized by Shiga and verotoxin B subunits, facilitating their binding and internalization into host cells. This receptor function explains why A4GALT activity directly influences the cellular response to bacterial toxins, which is a critical factor in the pathophysiology of toxin-mediated illnesses. Additionally, the P1 and P(k) antigens generated by A4GALT are involved in membrane microdomain formation and may affect lipid raft-associated signaling processes, with variable expression patterns observed across tissues. The enzyme's specificity for glycosphingolipid substrates positions it at a crossroads of glycobiology, plasma membrane dynamics and immunological recognition mechanisms that are studied using specific research reagents such as anti-A4GALT antibodies, ELISA kits and glycan profiling tools.
In the context of human disease, genetic variation in A4GALT underlies phenotypic diversity in the P1PK blood group, including rare null phenotypes that can impact transfusion compatibility and maternal-fetal immunology. Altered Gb3 expression also contributes to susceptibility to Shiga toxin-associated disease, where high Gb3 levels on endothelial cells and other targets correlate with increased cytotoxic damage during infection. Beyond infectious disease, Gb3 and its synthase have been explored in cancer biology, as glycosphingolipid profiles are often remodeled in tumors and may affect tumor cell behavior and immune recognition. Emerging research, including novel cellular and organoid models, also suggests that modulating A4GALT expression could influence pathological processes in conditions such as Fabry disease by altering Gb3 accumulation and downstream vascular or cellular dysfunction, highlighting its potential as a therapeutic and biomarker target across diverse biomedical applications.
Alternate Names for A4GALT
A4GALT; alpha 1,4-galactosyltransferase; alpha 1,4 galactosyltransferase (globotriaosylceramide synthase, P blood group); lactosylceramide 4-alpha-galactosyltransferase; A14GALT; CD77 synthase; Gb3 synthase; Gb3S; globotriaosylceramide synthase; P(k)
Loading ......
